GGT Test

Your standard blood panel includes a handful of liver enzymes, but GGT (gamma-glutamyl transferase) is usually not one of them. That matters, because GGT can start climbing years before the tests on your routine panel look abnormal. It picks up signals of liver stress from alcohol, excess body fat, medications, and metabolic strain that ALT and AST may miss entirely.

What makes GGT especially interesting from a prevention standpoint is that it is not just a liver marker. Large studies involving millions of people have linked higher GGT levels to increased risk of heart disease, diabetes, cancer, and earlier death from all causes, even after accounting for traditional risk factors. If you are trying to catch problems early, this is a number worth knowing.

What GGT Actually Does

GGT sits on the outer surface of cells, especially liver and bile duct cells. Its job is to break down glutathione, your body's most abundant internal antioxidant, so the building blocks can be recycled back into cells to make fresh glutathione. Think of it as part of your cellular recycling crew: it dismantles spent antioxidant molecules so the raw materials can be reused.

When your liver faces oxidative stress (damage from unstable oxygen molecules that accumulate during inflammation, toxic exposures, or metabolic overload), cells ramp up GGT production to recycle more glutathione faster. Some of that extra enzyme spills into your bloodstream, and that is what the lab measures. A rising GGT level means your liver's recycling system is working overtime.

Heart Disease and Cardiovascular Risk

GGT's connection to heart disease is one of the strongest and most consistent findings in the research. Catalytically active GGT has been found inside atherosclerotic plaques (the fatty deposits that clog arteries), suggesting the enzyme may play a direct role in plaque development rather than merely reflecting background risk.

A meta-analysis pooling 23 studies and over one million participants found that people with high GGT levels were about 62% more likely to die from cardiovascular disease. The risk follows a dose-response pattern: for every 10 U/L increase in GGT, the risk of cardiovascular death rises by roughly 10%. In the UK Biobank study of roughly 300,000 participants followed for nearly 12 years, even values considered "normal" by lab standards carried graded risk. A GGT of 60 U/L (the typical male upper limit) was associated with a 43% higher risk of cardiovascular death compared to a GGT of 14.5 U/L.

Sources: Rahmani et al. (2019 meta-analysis); Ho et al. (UK Biobank, 2022); Choi et al. (Korean National Health Database, 2018).

What this means for you: even if your GGT falls within the lab's printed "normal" range, a level in the upper half of that range deserves attention. The risk gradient is continuous, meaning lower is generally better, and values above roughly 50 U/L are where the risk curve steepens for most outcomes.

Cancer Associations

GGT levels also predict cancer risk, particularly for cancers of the digestive system. In a Korean study following over 1.6 million people for 17 years, those in the highest GGT group (60 IU/L or above) were roughly 6 to 7 times more likely to develop liver cancer compared to those with the lowest levels. The association held for both men and women and persisted even after excluding cancers diagnosed in the first five years (which helps rule out the possibility that an undetected cancer was driving the elevated GGT).

Beyond liver cancer, a meta-analysis of 14 studies involving 1.79 million participants found that people in the top third of GGT levels had a 32% higher risk of developing any cancer and about double the risk of digestive organ cancers. The risk increased by roughly 4% for every 5 U/L increment. The Swedish AMORIS study of over 545,000 people confirmed similar dose-response patterns.

All-Cause Mortality

The broadest signal GGT sends is about long-term survival. A meta-analysis of 19 cohort studies covering more than 9.2 million participants found that people with the highest GGT levels had about 60% higher risk of dying from any cause compared to those with the lowest levels. Each 5 U/L increase was associated with about 7% higher mortality risk, and the relationship was linear: there was no safe threshold below which the number stopped mattering.

The Korean nationwide cohort of 9.7 million people reinforced these findings. In the highest GGT tertile, all-cause mortality risk was 33% higher and liver disease mortality risk was nearly 7 times higher compared to the lowest tertile. These associations held regardless of smoking status, alcohol consumption, or prior history of cardiovascular disease or cancer.

Liver Disease and Fatty Liver

GGT has long been used to evaluate liver problems, though its value goes well beyond diagnosing obvious disease. In the context of metabolic dysfunction-associated steatotic liver disease (the current term for fatty liver disease not caused by heavy alcohol use), GGT rises as the liver accumulates fat and becomes inflamed. It is one of the components of the LiverRisk score, which predicts long-term liver outcomes in people without known liver disease.

The ratio of GGT to HDL cholesterol has shown promise as a simple screening tool for fatty liver. In adults with obesity being evaluated for bariatric surgery, this ratio had an accuracy of 81% for identifying fatty liver disease. The ratio appears especially useful in younger adults aged 20 to 40 and in certain ethnic groups.

Metabolic Disease and Diabetes Risk

Elevated GGT in otherwise healthy-looking people can be an early warning sign of metabolic trouble ahead. In a study of adolescents, those with higher GGT levels were about 2 to 3 times more likely to develop metabolic syndrome (a cluster of conditions including high blood sugar, high blood pressure, and excess abdominal fat) over the following decade. In younger adults from the Bogalusa Heart Study, higher GGT predicted future development of prediabetes and type 2 diabetes.

One important caveat: a genetic analysis technique called Mendelian randomization suggests the GGT-diabetes link may reflect shared underlying causes (like excess body fat driving both GGT and diabetes) rather than GGT directly causing diabetes. This does not diminish the marker's usefulness for spotting metabolic risk early, but it means lowering your GGT will not necessarily prevent diabetes on its own.

Reference Ranges

GGT levels differ substantially between men and women, and they climb with age, especially in women. Labs typically use sex-specific upper limits, but the threshold where health risk begins is lower than most lab ranges suggest. Your individual trend matters more than any single cutpoint.

These tiers are drawn from published research, including the IFCC multicenter study for standard ranges and UK Biobank data for risk-stratified thresholds. Your lab may use different testing methods and cutpoints. Compare your results within the same lab over time for the most meaningful trend.

The key takeaway from the UK Biobank data is that mortality risk starts rising well below the printed upper limit. A GGT of 48 U/L in women (the standard upper limit in some labs) already carries about 15% higher all-cause mortality compared to a level of 14.5 U/L. For a man at 60 U/L, that gap widens to 31%. Aiming for the lower end of the range, not just staying under the upper limit, appears to matter.

Why One Reading Is Not Enough

GGT has a within-person biological variation of about 8.9%, meaning your level can shift by nearly 10% from one draw to the next even if nothing about your health has changed. That is actually quite stable compared to other liver enzymes (ALT varies by about 20%), but it still means a single reading can mislead you. In a large U.S. study, about 12% of initially elevated GGT results came back normal on a second draw roughly two and a half weeks later.

The real power of GGT comes from tracking your personal trend. Because the variation between different people (41.7%) is much larger than the variation within the same person over time (8.9%), population-based reference ranges are a blunt tool. Your own baseline and trajectory tell a sharper story. Get a baseline reading, retest in 3 to 6 months if you are making changes (cutting alcohol, losing weight, adjusting medications), and track at least annually after that. A rising trend, even within the "normal" range, is a signal to investigate.

When Results Can Be Misleading

Several common factors can push your GGT up or pull it down without reflecting a true change in your liver health. Being aware of these can save you from unnecessary worry or false reassurance.

• Body weight: BMI is one of the strongest drivers of GGT levels in both sexes. Gaining or losing significant weight between tests will shift your number in the same direction, making it hard to tell whether a change reflects liver health or body composition.
• Time of day and fasting status: GGT tends to be lower later in the day and rises with longer fasting. If you get blood drawn at 7 AM fasting for one test and 2 PM non-fasting for the next, the comparison is unreliable. Try to test at the same time and fasting state each time.
• Medications: Anticonvulsants (phenytoin, barbiturates), certain antidepressants, warfarin, and thiazide diuretics can all raise GGT as a side effect of how the liver processes them, not because they are causing liver damage. If you start or stop one of these medications between tests, flag it.
• Recent surgery or acute illness: Any significant physical stress, from a heart attack to thoracic surgery (where over half of patients showed GGT increases), can temporarily spike your level. Wait at least 4 to 6 weeks after an acute event before interpreting a GGT result as your baseline.